



Curriculum Vitae

Personal information **Hrvoje Rimac**

Work experience

06/2025 - present

Employer: Agency for Medicinal Products and Medical Devices (HALMED)

Position: Assessor for European Affairs

Activities: assessment of pharmacology and PK studies in centralised procedures and assessment of bioequivalence studies and biowaivers in national, decentralised and centralised procedures, as well as providing scientific advice for central marketing authorisation procedures.

Country: Croatia

05/2024 - 05/2025

Employer: Agency for Medicinal Products and Medical Devices (HALMED)

Position: Associate for Non-Clinical and Clinical Assessment

Activities: assessment of pharmacology and PK studies in centralised procedures and assessment of bioequivalence studies and biowaivers in national, decentralised and centralised procedures, as well as providing scientific advice for central marketing authorisation procedures.

Country: Croatia

01/2023 - 02/2024

Employer: Selvita Ltd

Position: Senior Scientist II (In vitro Pharmacology Department)

Activities: Providing scientific and experimental support in preclinical research for external stakeholders. Ensuring input for proposal preparation, performing in vitro assays, and delivering project reports.

Country: Croatia

12/2021 - 01/2023

Employer: Faculty of Pharmacy and Biochemistry, University of Zagreb, Department of Medicinal Chemistry

Position: Assistant Professor

Activities: Course leader of a mandatory graduate level course "Drug Metabolism". Collaborator in a mandatory graduate level course "Medicinal Chemistry 1". Course leader of elective graduate level courses "Biochemical Basis of Toxicity of Endobiotics and Xenobiotics", "Medicinal Chemistry". Collaborator in an elective graduate level course "Drug Design". Research interest: in vitro drug metabolism, cytochrome P450 enzymes, protein-ligand interactions, computational chemistry, quantitative structure-activity relationship (statistical modelling)

Country: Croatia

09/2017 - 12/2021

Employer: Faculty of Pharmacy and Biochemistry, University of Zagreb, Department of Medicinal Chemistry

Position: Postdoctoral Researcher/Assistant

Country: Croatia

01/2012 - 09/2017

Employer: Faculty of Pharmacy and Biochemistry, University of Zagreb, Department of Medicinal Chemistry

Position: Teaching and Research Assistant

Country: Croatia

Education and training

10/2014 - 01/2022

Degree: University Specialist of Drug Development (univ. spec. pharm.)

Institution: Faculty of Pharmacy and Biochemistry, University of Zagreb

Country: Croatia

10/2013 - 09/2017

Degree: Doctor of Pharmaceutical Sciences (PhD)

Institution: Faculty of Pharmacy and Biochemistry, University of Zagreb

Country: Croatia

10/2011 - 09/2013

Degree: Master of Engineering in Molecular Biotechnology (mag. ing. mol. biotechn.)

Institution: Faculty of Food Technology and Biotechnology, University of Zagreb

Country: Croatia

10/2006 - 09/2011

Degree: Master of Pharmacy (mag. pharm.)

Institution: Faculty of Food Technology and Biotechnology, University of Zagreb

Country: Croatia

Additional information

Publications

1. CYP3A4-Mediated Metabolism and Drug-Drug Interaction Potential of Abemaciclib and Letrozole in vitro; M. Kondža, L. Turković, H. Rimac, M. Sertić; Chem Biodiversity, 2026, 23:e02344. <https://doi.org/10.1002/cbdv.202502344>
2. Design, synthesis and antiplasmodial evaluation of new amide-, carbamate-, and ureido-type harmicines.

- M. Marinović, H. Rimac, L. Pessanha de Carvalho, C. Rôla, S. Santana, K. Pavić, J. Held, M. Prudêncio, Z. Rajčić; *Bioorg. Med. Chem.*, 2023, 94, 117468. <https://doi.org/10.1016/j.bmc.2023.117468>
3. Cyclodextrin-Based Displacement Strategy of Sterigmatocystin from Serum Albumin as a Novel Approach for Acute Poisoning Detoxification; D. Jakšić, M. Segvić Klarić, H. Rimac, R. Kerep, I. Piantanida; *Int J Mol Sci*, 2023, 24, 4485. <https://doi.org/10.3390/ijms24054485>
 4. Exploring the Potential and Identifying Withania somnifera Alkaloids as Novel Dihydrofolate Reductase (DHFR) Inhibitors by the AlteQ method; G. Krishnamoorthy, H. Rimac, N. Palko, M. Grishina; *J Biomol Struct Dyn*, 2023, 10, 1-14. <https://doi.org/10.1080/07391102.2023.2175727>
 5. AlteQ: A New Complementarity Principle-Centered Method for the Evaluation of Docking Poses; S. Kandagalla, M. Grishina, J. Novak, H. Rimac, B.S. Sharath, V. Potemkin; *J Biomol Struct Dyn*, 2023, 11, 1-15. <https://doi.org/10.1080/07391102.2023.2166120>
 6. Determination of Naphthoquinones in Invasive Alien Plants *Impatiens glandulifera* Royle and *I. balfourii* Hook.f. from Croatia; Ž. Maleš, A.-M. Domijan, I. Duka, T. Marić, M. Bojić, H. Rimac, B. Mitić, D. Hruševar, K. Barišić, D. Verbanac; *Croat Chem Acta*, 2022, 95, 1, 1-5. <https://doi.org/10.5562/cca3911>
 7. In Silico Screening of Quorum Sensing Inhibitor Candidates Obtained by Chemical Similarity Search; S.B. Shekarappa, H. Rimac, J. Lee; *Molecules*, 2022, 27, 15, 4887. <https://doi.org/10.3390/molecules27154887>
 8. Withasomniferol C, a New Potential SARS-CoV-2 Main Protease Inhibitor from the *Withania somnifera* Plant Proposed by In Silico Approaches; S. Kandagalla, H. Rimac, G. Krishnamoorthy, J. Novak, M. Grishina, V. Potemkin; *PeerJ*, 2022, 10, e13374, 26. <https://doi.org/10.7717/peerj.13374>
 9. Synthesis of Arylmethylene-bis(3-hydroxy-5,5-dimethylcyclohex-2-en-1-one) Derivatives and Their Effect on Tyrosinase Activity; E. Veljović, H. Rimac, M. Salihović, S. Špirotović-Hallilović, A. Osmanović, N. Kovač, E. Kiršek, E. Članjak-Kudra, D. Špirotović, M. Bojić; *Croat Chem Acta*, 2021, 94, 3, 1-9. <https://doi.org/10.5562/cca3857>
 10. Antibacterial Fractions from *Erodium cicutarium* Exposed – Clinical Strains of *Staphylococcus aureus* in Focus; V. Ljoljić Bilić, U.M. Gašić, D. Milojković-Opsenica, H. Rimac, J. Vuković Rodríguez, J. Vlajinić, D. Brlek-Gorski, I. Kosalec; *Antibiotics*, 2022, 11, 492. <https://doi.org/10.3390/antibiotics11040492>
 11. COVID-19 Infection and Neurodegeneration: Computational Evidence for Interactions between the SARS-CoV-2 Spike Protein and Monoamine Oxidase Enzymes; L. Hok, H. Rimac, J. Mavri, R. Vianello; *Comput Struct Biotechnol J*, 2022, 20, 1254-1263. <https://doi.org/10.1016/j.csbj.2022.02.020>
 12. A Triterpene Glochidon from *Phyllanthus debilis*: Isolation, Computational Studies, and Antidiabetic Activity Evaluation; A. Verma, P. Pathak, H. Rimac, H. Khalilullah, V. Kumar, M. Grishina, V. Potemkin, B. Ahmed; *Biocatal Agric Biotechnol*, 2021, 36, 102138. <https://doi.org/10.1016/j.bcab.2021.102138>
 13. Proposition of a New Allosteric Binding Site for Potential SARS-CoV-2 3CL Protease Inhibitors by Utilizing Molecular Dynamics Simulations and Ensemble Docking; J. Novak, H. Rimac, S. Kandagalla, P. Pathak, V. Naumovich, M. Grishina, V. Potemkin; *J Biomol Struct Dyn*, 2022, 40, 19, 9347-9360. <https://doi.org/10.1080/07391102.2021.1927845>
 14. Complementarity Principle in Terms of Electron Density for the Study of EGFR Complexes; S. Kandagalla, H. Rimac, V.A. Potemkin, M.A. Grishina; *Future Med Chem*, 2021, 13, 10, 863-875. <https://doi.org/10.4155/fmc-2020-0265>
 15. Use of the Complementarity Principle in Docking Procedures: A New Approach for Evaluating the Correctness of Binding Poses; H. Rimac, M. Grishina, V. Potemkin; *J Chem Inf Model*, 2021, 61, 1801–1813. <https://doi.org/10.1021/acs.jcim.0c01382>
 16. Investigation of the Newly Characterized Baimantuoluamide A and B Alkaloids as Potential Cyclin-Dependent Kinase 4 (CDK4) Inhibitors Using Molecular Docking and Molecular Dynamics Simulations; G. Krishnamurti, H. Rimac, V. Potemkin, M. Grishina; *J Mol Struct*, 2021, 1230, 129925. <https://doi.org/10.1016/j.molstruc.2021.129925>
 17. Can Natural Products Stop the SARS-CoV-2 virus? A Docking and Molecular Dynamics Study of a Natural Product Database; J. Novak, H. Rimac, S. Kandagalla, M.A. Grishina, V.A. Potemkin; *Future Med Chem*, 2021, 30, 4, 363-378. <https://doi.org/10.4155/fmc-2020-0248>
 18. Computational Insights into the Binding Mode of Curcumin Analogues against EP300 HAT Domain as Potent Acetyltransferase Inhibitors; S. Kandagalla, B.S. Sharath, H. Rimac, M.A. Grishina, V.A. Potemkin, M. Hanumanthappa; *J Mol Graph Model*, 2020, 101, 107756. <https://doi.org/10.1016/j.jmgm.2020.107756>
 19. Hybrid Quinazoline 1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study; P. Pathak, H. Rimac, M. Grishina, A. Verma, V. Potemkin; *ChemMedChem*, 2021, 16, 5, 822-838. <https://doi.org/10.1002/cmde.202000646>
 20. Pathway Enrichment Analysis of Virus-Host Interactome and Prioritization of Novel Compounds Targeting the Spike Glycoprotein Receptor Binding Domain-Human Angiotensin-Converting Enzyme 2 Interface to Combat SARS-CoV-2; G. Pavan, B.S. Sharath, H. Rimac, P. Patil, S. Kumari Nalilu, S. Kandagalla, P. Shetty; *J Biomol Struct Dyn*, 2022, 40, 6, 2701-2714. <https://doi.org/10.1080/07391102.2020.1841681>
 21. Attenuation of Hepatic and Breast Cancer Cells by Polygonatum verticillatum Embedded Silver Nanoparticles; M. Pathak, P. Pathak, H. Rimac, M. Grishina, U. Bagale, V. Kumar, R. Majee, V. Potemkin, A. Verma; *Biocatal Agric Biotechnol*, 2020, 30101863. <https://doi.org/10.1016/j.bcab.2020.101863>
 22. Inhibitory Effect of Acacetin, Apigenin, Chrysin and Pinocembrin on Human Cytochrome P450 3A4; M. Kondža, H. Rimac, Ž. Maleš, P. Turčić, I. Čavar, M. Bojić; *Croat Chem Acta*, 2020, 93, 1, 1-7. <https://doi.org/10.5562/cca3652>
 23. Electron Density Analysis of CDK Complexes Using the AlteQ Method; H. Rimac, M.A. Grishina, V.A. Potemkin; *Future Med Chem*, 2020, 12, 15, 1387-1397. <https://doi.org/10.4155/fmc-2020-0076>
 24. Indomethacin Increases Quercetin Affinity for Human Serum Albumin: A Combined Experimental and Computational Study and its Broader Implications; H. Rimac, T. Tandarić, R. Vianello, M. Bojić; *Int J Mol Sci*, 2020, 21, 16, 5740. <https://doi.org/10.3390/ijms21165740>
 25. Influence of Flavonoids' Lipophilicity on Platelet Aggregation; I. Babić, M. Bojić, Ž. Maleš, R. Zadro, K. Gojčeta, I. Duka, H. Rimac, I. Jukić; *Acta pharm*, 2019, 69, 4, 607-619. <https://doi.org/10.2478/acph-2019-0040>
 26. The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity; M. Bojić, M. Kondža, H. Rimac, G. Benković, Ž. Maleš; *Molecules*, 2019, 24, 17, 3174. <https://doi.org/10.3390/molecules24173174>
 27. Characterization of O-demethylations and Aromatic Hydroxylations Mediated by Cytochromes P450 in the Metabolism of Flavonoid Aglycons; G. Benković, H. Rimac, Ž. Maleš, S. Tomić, Z. Lončar, M. Bojić; *Croat Chem Acta*, 2019, 92, 1, 115-123. <https://doi.org/10.5562/cca3528>
 28. Primaquine Hybrids as Promising Antimycobacterial and Antimalarial Agents; K. Pavić, I. Perković, Š. Pospišilova, M. Machado, D. Fontinha, M. Prudencio, J. Jampilek, A. Coffey, L. Endersen, H. Rimac, B. Zorc; *Eur J Med Chem*, 2018, 143, 769-779. <https://doi.org/10.1016/j.eimech.2017.11.083>
 29. Warfarin and Flavonoids do not Share the Same Binding Region in Binding to the IIA Subdomain of Human Serum Albumin; H. Rimac, C. Dufour, Ž. Debeljak, B. Zorc, M. Bojić; *Molecules*, 2017, 22, 7, 1153-1. <https://doi.org/10.3390/molecules22071153>
 30. Displacement of Drugs from Human Serum Albumin: From Molecular Interactions to Clinical Significance; H. Rimac, Ž. Debeljak, M. Bojić, L. Miller; *Curr Med Chem*, 2017, 24, 18, 1930-1947. <https://doi.org/10.2174/0929867324666170202152134>
 31. Structural and Electronic Determinants of Flavonoid Binding to Human Serum Albumin: An Extensive Ligand-Based Study; H. Rimac, Ž. Debeljak, D. Šakić, T. Weitner, M. Gabričević, V. Vrček, B. Zorc, M. Bojić; *RSC Adv*, 2016, 6, 79, 75014-75022. <https://doi.org/10.1039/C6RA17796D>

Projects

1. „Development of green analytical methods for identifying factors of interindividual pharmacokinetic variability of targeted anticancer drugs“ (2025 – 2028), funded by Croatian Science Foundation
2. „Novel bioanalytical solutions in personalized breast cancer treatment“ (2020 – 2025), funded by Croatian

Science Foundation

3. „Harmine derivatives as potential antimalarics“ (2018 – 2023), funded by Croatian Science Foundation
4. „Metabolism and interactions of biologically active compounds and QSAR“ (2015 – 2018), funded by Croatian Science Foundation
5. “Structural basis of flavonoids responsible for metabolic and distribution interactions, and antiaggregatory effect” (2013 – 2014), funded by the University of Zagreb
6. “Biologically actives compounds, metabolites, and QSAR” (2007 – 2013), funded by the Ministry of Science, Education and Sport of the Republic of Croatia

Memberships

1. The Best Young Scientist Award in the field of pharmaceutical and medicinal chemistry (The Croatian Chemical Society, 2021)
2. The Best Young Scientist Award (Faculty of Pharmacy and Biochemistry, University of Zagreb, 2020)

Other Relevant Information